


REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)



In re Application of

BENDIG

Application Number

08/186269

Filed

1-25-94

Class and Unit

Examiner

Paper No. 16

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(vi) to the application file record of the above-identified ABANDONED application, which is: CHECK ONE

- ☒ (A) referred to in United States Patent Number 5840299, column _____
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Barbara J. Hendley
Signature

Barbara J. Hendley
Typed or printed name

3-22-00
Date

FOR PTO USE ONLY

Approved by: TW
(Initials)

Unit: F111



US005840299A

United States Patent [19]**Bendig et al.**[11] **Patent Number:** **5,840,299**[45] **Date of Patent:** **Nov. 24, 1998**[54] **HUMANIZED ANTIBODIES AGAINST
LEUKOCYTE ADHESION MOLECULE
VLA-4**[75] **Inventors:** **Mary M. Bendig**, London; **Olivier J. Léger**, Hertfordshire; **José Saldanha**, Enfield Middlesex; **S. Tarran Jones**, Radlett, all of United Kingdom; **Ted A. Yednock**, Fairfax, Calif.[73] **Assignee:** **Athena Neurosciences, Inc.**, South San Francisco, Calif.[21] **Appl. No.:** **561,521**[22] **Filed:** **Nov. 21, 1995****Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 186,269, which is a continuation-in-part of PCT/US95/01219 Jan. 25, 1995, abandoned.

[51] **Int. Cl.⁶** **A61K 39/395**; C07K 16/28; C12P 21/08; C12N 15/13[52] **U.S. Cl.** **424/133.1**; 424/130.1; 424/141.1; 424/143.1; 424/144.1; 424/153.1; 424/154.1; 424/173.1; 435/7.1; 435/7.2; 435/7.21; 435/7.24; 435/69.6; 435/172.3; 435/251.3; 435/320.1; 530/387.3; 530/388.73; 530/388.75; 530/388.22; 536/23.53[58] **Field of Search** 424/130.1, 133.1, 424/141.1, 143.1, 144.1, 153.1, 154.1, 173.1; 435/69.6, 172.3, 252.3, 320.1, 7.1, 7.2, 7.21, 7.24; 536/23.4, 23.5, 23.53; 530/387.1, 387.3, 388.2, 388.22, 388.7, 388.73, 388.75[56] **References Cited****U.S. PATENT DOCUMENTS**5,260,210 11/1993 Rubin et al. 435/240.23
5,530,101 6/1996 Queen et al. 530/387.3**FOREIGN PATENT DOCUMENTS**239400 9/1987 European Pat. Off. C12N 15/00
330506 8/1989 European Pat. Off. C07K 15/06
WO 90/07861 7/1990 WIPO C12P 21/00
WO 91/03252 3/1991 WIPO A61K 37/10
91/05038 4/1991 WIPO C12N 5/06
WO 93/15764 8/1993 WIPO A61K 39/395**OTHER PUBLICATIONS**Lisak et al. *J. Neurol. Sciences* 62: 281-293 (1983).
Teitelbaum et al. *PNAS* 89: 137-141 (1992).
Weiner et al. *Science* 259: 1321-1324 (1993).
Racke et al. *J. Neuroimmunol.* 46: 175-184 (1993).
Karussis et al. *PNAS* 90: 6400-6404 (1993).Cannella et al. *Ann Neurol.* 37: 424-435 (1995).
Washington et al. *Ann Neurol* 35: 89-97 (1994).
Dore-Duffy et al. in *Frontiers in Cerebral Vascular Biology: Transport and its Regulation* (eds) Dreues and Betz Plenum Press Ny 1993 pp. 243-248.Monshizadegan et al., "VLA-4-dependent adhesion activities of U937 cells and guinea pig bronchoalveolar lavage leukocytes", 1993, *Agents Actions* 39, pp. C177-C179.Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting the importance of framework residues on loop conformation", 1991, *Protein Engineering*, vol. 4, No. 7, pp. 773-783.Yednock et al. "Prevention of experimental autoimmune encephalomyelitis by antibodies against $\alpha 4 \beta 1$ integrin", 1991, *Letters to Nature*, vol. 356, pp. 63-66.W. J. Harris and S. Emery, "Therapeutic antibodies—the coming of age", 1993, *Tibtech*, vol. 11, pp. 42-45.S. C. Emery and J. R. Adair, "Humanised monoclonal antibodies for therapeutic applications", 1994, *Exp. Opin. Invest. Drugs*, vol. 3, pp. 241-251.S. M. Edgington, "How Sweet It Is: Selectin-Mediating Drugs", 1992, *Bio/Technology*, vol. 10, pp. 383-389.Elises et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site", 1990, *Cell*, vol. 60, pp. 577-584.Dijkstra et al., "Multiple sclerosis: some possible therapeutic opportunities", 1993, *Tips Reviews*, vol. 14, pp. 124-129.A. Mountain and J.R. Adair, "Engineering Antibodies for Therapy", 1992, *Biotech Genetic Engineering Reviews*, vol. 10, pp. 10-13.P.A. Ward and M.S. Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy", 1994, *Therapeutic Immunol.*, vol. 10, pp. 165-171.L. K. Jolliffe, "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering", 1993, *Intern Rev Immunol.*, vol. 10, pp. 241-250.

Albelda Faseb J. 8: 504-512 (1994).

Kahan Curr Opin Immunology 4: 553-560 (1992).

Natanson et al. *Ann Intern Med.* 120: 771-783 (1994).Dalakas *Ann. Neurol.* 37(51): 52-513 (1995).Paul (ed) *Fundamental Immunology* Raven Press NY 1993 p. 242 only.**Primary Examiner**—Lila Feisee**Assistant Examiner**—Phillip Gambel**Attorney, Agent, or Firm**—Townsend & Townsend & Crew LLP

[57]

ABSTRACT

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.

29 Claims, 16 Drawing Sheets